Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

d increased personal and personal related costs for our technical operations. For the year ended December 31, 2008, increased expenses resulted from investments in our development programs, increased medical education activities and increased marketing activities.

Our effective income tax rate was a benefit of 76.3 percent and an expense of 18.0 percent for the quarters ended December 31, 2008 and 2007, respectively and an expense of 22.4 percent and 29.7 percent for the year ended December 31, 2008 and 2007, respectively. Our income tax expense includes federal, state and foreign income taxes at statutory rates and the effects of various permanent differences. The decrease in the 2008 rate as compared to 2007 is primarily due to the impact of the orphan drug credit for maribavir and the decreased level of income before taxes.

Working Capital Highlights

As of December 31, 2008, ViroPharma's working capital was approximately $305.4 million, which represents a $289.0 million decrease from December 31, 2007, caused by a $366.4 million decrease in the fourth quarter of 2008 mainly related to the acquisition of Lev ($380.2 million), offset slightly by operating cash flows. Cash flow from operating activities for the three months and year ended December 31, 2008 was $0.6 million and $91.4 million, respectively.

Business Development Highlights

In October 2008, we completed our acquisition of Lev. Lev was a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. The terms of the merger agreement provided for the conversion of each share of Lev common stock into upfront consideration in the aggregate amount of $442.9 million, or $2.75 per Lev share, comprised of $2.25 per share in cash and $0.50 per share in ViroPharma common stock, and contingent consideration (CVRs) of up
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Nevada City, CA (PRWEB) August 28, 2014 ... and sanitation products for the food processing industry, is ... conducting a side-by side comparison of the E2 soap ... Q E2 Sanitizing Foam Soap . Hand hygiene ... pathogens in the food processing environment. Six key criteria ...
(Date:8/28/2014)... WEST LAFAYETTE, Ind. A new research ... "nanomechanical" properties of tiny structures undergoing stress ... insights to improve designs for microelectronics and ... spectroscopy, reveals information about how heating and ... their mechanical properties. Researchers have discussed the ...
(Date:8/28/2014)... The ability for organizations to attract ... allow individuals to perform at the highest of levels, ... looking to compete in this post–recession era. The ... as the sector increasingly focuses on the importance of ... have real results on the organization's development and the ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Sterlitech is ... polymeric membranes to its stable of products . ... molecular weight cut-offs and include membrane filters with surface ... increase in customer demand for our membrane process testing ... variety of flat sheet membranes,” explains Sterlitech President Mark ...
Breaking Biology Technology:Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Sterlitech Corporation Enhances Its Selection of Flat Sheet Membrane Filters 2
... - Third Quarter 2007 Financial Results and Business Update - ... - Thursday, November 15, 11:30 a.m. Eastern Time -, ... , TSX: WHT), a developer of mechanical circulatory,support systems, will ... of the results and a business update in a,teleconference at ...
... experts have,abandoned the over 100 year old tuberculin ... assays such as QuantiFERON(R)-TB Gold (QFT(TM)),for screening patients ... (such as anti-TNF-a therapy). In recommendations,published in the ... the use of QFT(TM) in place of the ...
... and TORONTO, Nov. 13 /PRNewswire/ - BioRelix, ... based therapeutic agents and,Dalton Medicinal Chemistry, have ... therapeutics. Dalton Medicinal Chemistry will utilize ... novel classes of compounds against selected,RiboSwitch targets. ...
Cached Biology Technology:Swiss Experts Recommend QuantiFERON(R)-TB Gold for Tuberculosis Infection Screening Prior to Initiating anti-TNF-a Therapy 2Swiss Experts Recommend QuantiFERON(R)-TB Gold for Tuberculosis Infection Screening Prior to Initiating anti-TNF-a Therapy 3BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology 2
(Date:8/31/2014)... past several decades, malaria diagnosis has changed very little. After ... the blood across a glass slide, stains it with a ... parasite, which causes the disease. This approach gives an accurate ... an important measure of disease severity but is not ... research team from the Singapore-MIT Alliance for Research and Technology ...
(Date:8/29/2014)... (Aug. 29, 2014) Scientists at the Barshop Institute ... of Medicine at the UT Health Science Center at ... the tissues of the longest-lived rodent, the naked mole ... the cells of naked mole rats protects and alters ... damaged and obsolete proteins. , The factor also protects ...
(Date:8/29/2014)... how the repeated climatic shifts over the last ... genetic diversity, a team of researchers led by ... Carnaval developed a new biodiversity metric called "phylogeographic ... the genetic variation within species is restricted in ... of biology, and 14 other researchers from institutions ...
Breaking Biology News(10 mins):A new way to diagnose malaria 2A new way to diagnose malaria 3Factor in naked mole rat's cells enhances protein integrity 2CCNY team defines new biodiversity metric 2
... complex societies, researchers are sequencing the genomes of social insects. ... Edition of Proceedings of the National Academy of Sciences ... harvester ant, Pogonomyrmex barbatus . A team, lead ... Gadau, sequenced one of the genomes and set out to ...
... ON New research from the University of Toronto could ... who suffer from obstructive sleep apnea. In a recent ... scientists from the University demonstrated that repeated obstruction of the ... of this chemical helps the brain learn to breathe more ...
... 2011 A scientist from The Scripps Research Institute has identified ... blood clot formation. The molecule could become a target for ... diseases such as Hemophilia A. The findings, from a ... published in a recent edition of Journal of Biological ...
Cached Biology News:Seeking social genes 2Scripps Research scientist discovers natural molecule indirectly prevents stable clot formation 2Scripps Research scientist discovers natural molecule indirectly prevents stable clot formation 3
... causing shortages in your laboratory or fellow researchers ... distractions, problems and delays. • ... endeavour! Bring us your idea and let us ... work under ISO 9001 quality assurance in design, ...
...
... Topoisomerase I from vaccinia virus is a ... positive and negative superhelical turns (also called ... DNA. The product of the reaction is ... positive or negative superhelical turns. DNA Topoisomerase ...
Applications include ELISA, immunochemistry, and Western blotting. Working Concentrations: ELISA: 0.005-0.05 U/ml, immunohisto/cytochemistry: 0.25-0.5 U/ml, Western blot: 0.1-0.25 U/ml....
Biology Products: